Association of menopausal vasomotor symptoms with increased bone turnover during the menopausal transition

Carolyn J. Crandall, Chi Hong Tseng, Sybil L. Crawford, Rebecca C. Thurston, Ellen B Gold, Janet M. Johnston, Gail A. Greendale

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

The purpose of this study was to determine the longitudinal association between menopausal vasomotor symptoms (VMS) and urinary N-telopeptide level (NTX) according to menopausal stage. We analyzed data from 2283 participants of the Study of Women's Health Across the Nation, a longitudinal community-based cohort study of women aged 42 to 52 years at baseline. At baseline and annually through follow-up visit 8, participants provided questionnaire data, urine samples, serum samples, and anthropometric measurements. Using multivariable repeated-measures mixed models, we examined associations between annually assessed VMS frequency and annual NTX measurements. Our results show that mean adjusted NTX was 1.94 nM of bone collagen equivalents (BCE)/mM of creatinine higher among early perimenopausal women with any VMS than among early perimenopausal women with no VMS (p<.0001). Mean adjusted NTX was 2.44 nM BCE/mM of creatinine higher among late perimenopausal women with any VMS than among late perimenopausal women with no VMS (p=.03). Among premenopausal women, VMS frequency was not significantly associated with NTX level. When NTX values among women with frequent VMS (≥6 days in past 2 weeks) were expressed as percentages of NTX values among women without frequent VMS, the differences were 3% for premenopausal women, 9% for early perimenopausal women, 7% for late perimenopausal women, and 4% for postmenopausal women. Adjustment for serum follicle-stimulating hormone (FSH) level greatly reduced the magnitudes of associations between VMS and NTX level. We conclude that among early perimenopausal and late perimenopausal women, those with VMS had higher bone turnover than those without VMS. Prior to the final menstrual period, VMS may be a marker for risk of adverse bone health.

Original languageEnglish (US)
Pages (from-to)840-849
Number of pages10
JournalJournal of Bone and Mineral Research
Volume26
Issue number4
DOIs
StatePublished - Apr 2011

Fingerprint

Bone Remodeling
Bone and Bones
Creatinine
Collagen
Follicle Stimulating Hormone
Women's Health
Serum
Cohort Studies

Keywords

  • bone turnover
  • Hot flashes
  • NTX
  • urinary N-telopeptide
  • vasomotor symptoms

ASJC Scopus subject areas

  • Orthopedics and Sports Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Crandall, C. J., Tseng, C. H., Crawford, S. L., Thurston, R. C., Gold, E. B., Johnston, J. M., & Greendale, G. A. (2011). Association of menopausal vasomotor symptoms with increased bone turnover during the menopausal transition. Journal of Bone and Mineral Research, 26(4), 840-849. https://doi.org/10.1002/jbmr.259

Association of menopausal vasomotor symptoms with increased bone turnover during the menopausal transition. / Crandall, Carolyn J.; Tseng, Chi Hong; Crawford, Sybil L.; Thurston, Rebecca C.; Gold, Ellen B; Johnston, Janet M.; Greendale, Gail A.

In: Journal of Bone and Mineral Research, Vol. 26, No. 4, 04.2011, p. 840-849.

Research output: Contribution to journalArticle

Crandall, CJ, Tseng, CH, Crawford, SL, Thurston, RC, Gold, EB, Johnston, JM & Greendale, GA 2011, 'Association of menopausal vasomotor symptoms with increased bone turnover during the menopausal transition', Journal of Bone and Mineral Research, vol. 26, no. 4, pp. 840-849. https://doi.org/10.1002/jbmr.259
Crandall, Carolyn J. ; Tseng, Chi Hong ; Crawford, Sybil L. ; Thurston, Rebecca C. ; Gold, Ellen B ; Johnston, Janet M. ; Greendale, Gail A. / Association of menopausal vasomotor symptoms with increased bone turnover during the menopausal transition. In: Journal of Bone and Mineral Research. 2011 ; Vol. 26, No. 4. pp. 840-849.
@article{fcfbaa41059449fda5b850bc5cb300d3,
title = "Association of menopausal vasomotor symptoms with increased bone turnover during the menopausal transition",
abstract = "The purpose of this study was to determine the longitudinal association between menopausal vasomotor symptoms (VMS) and urinary N-telopeptide level (NTX) according to menopausal stage. We analyzed data from 2283 participants of the Study of Women's Health Across the Nation, a longitudinal community-based cohort study of women aged 42 to 52 years at baseline. At baseline and annually through follow-up visit 8, participants provided questionnaire data, urine samples, serum samples, and anthropometric measurements. Using multivariable repeated-measures mixed models, we examined associations between annually assessed VMS frequency and annual NTX measurements. Our results show that mean adjusted NTX was 1.94 nM of bone collagen equivalents (BCE)/mM of creatinine higher among early perimenopausal women with any VMS than among early perimenopausal women with no VMS (p<.0001). Mean adjusted NTX was 2.44 nM BCE/mM of creatinine higher among late perimenopausal women with any VMS than among late perimenopausal women with no VMS (p=.03). Among premenopausal women, VMS frequency was not significantly associated with NTX level. When NTX values among women with frequent VMS (≥6 days in past 2 weeks) were expressed as percentages of NTX values among women without frequent VMS, the differences were 3{\%} for premenopausal women, 9{\%} for early perimenopausal women, 7{\%} for late perimenopausal women, and 4{\%} for postmenopausal women. Adjustment for serum follicle-stimulating hormone (FSH) level greatly reduced the magnitudes of associations between VMS and NTX level. We conclude that among early perimenopausal and late perimenopausal women, those with VMS had higher bone turnover than those without VMS. Prior to the final menstrual period, VMS may be a marker for risk of adverse bone health.",
keywords = "bone turnover, Hot flashes, NTX, urinary N-telopeptide, vasomotor symptoms",
author = "Crandall, {Carolyn J.} and Tseng, {Chi Hong} and Crawford, {Sybil L.} and Thurston, {Rebecca C.} and Gold, {Ellen B} and Johnston, {Janet M.} and Greendale, {Gail A.}",
year = "2011",
month = "4",
doi = "10.1002/jbmr.259",
language = "English (US)",
volume = "26",
pages = "840--849",
journal = "Journal of Bone and Mineral Research",
issn = "0884-0431",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Association of menopausal vasomotor symptoms with increased bone turnover during the menopausal transition

AU - Crandall, Carolyn J.

AU - Tseng, Chi Hong

AU - Crawford, Sybil L.

AU - Thurston, Rebecca C.

AU - Gold, Ellen B

AU - Johnston, Janet M.

AU - Greendale, Gail A.

PY - 2011/4

Y1 - 2011/4

N2 - The purpose of this study was to determine the longitudinal association between menopausal vasomotor symptoms (VMS) and urinary N-telopeptide level (NTX) according to menopausal stage. We analyzed data from 2283 participants of the Study of Women's Health Across the Nation, a longitudinal community-based cohort study of women aged 42 to 52 years at baseline. At baseline and annually through follow-up visit 8, participants provided questionnaire data, urine samples, serum samples, and anthropometric measurements. Using multivariable repeated-measures mixed models, we examined associations between annually assessed VMS frequency and annual NTX measurements. Our results show that mean adjusted NTX was 1.94 nM of bone collagen equivalents (BCE)/mM of creatinine higher among early perimenopausal women with any VMS than among early perimenopausal women with no VMS (p<.0001). Mean adjusted NTX was 2.44 nM BCE/mM of creatinine higher among late perimenopausal women with any VMS than among late perimenopausal women with no VMS (p=.03). Among premenopausal women, VMS frequency was not significantly associated with NTX level. When NTX values among women with frequent VMS (≥6 days in past 2 weeks) were expressed as percentages of NTX values among women without frequent VMS, the differences were 3% for premenopausal women, 9% for early perimenopausal women, 7% for late perimenopausal women, and 4% for postmenopausal women. Adjustment for serum follicle-stimulating hormone (FSH) level greatly reduced the magnitudes of associations between VMS and NTX level. We conclude that among early perimenopausal and late perimenopausal women, those with VMS had higher bone turnover than those without VMS. Prior to the final menstrual period, VMS may be a marker for risk of adverse bone health.

AB - The purpose of this study was to determine the longitudinal association between menopausal vasomotor symptoms (VMS) and urinary N-telopeptide level (NTX) according to menopausal stage. We analyzed data from 2283 participants of the Study of Women's Health Across the Nation, a longitudinal community-based cohort study of women aged 42 to 52 years at baseline. At baseline and annually through follow-up visit 8, participants provided questionnaire data, urine samples, serum samples, and anthropometric measurements. Using multivariable repeated-measures mixed models, we examined associations between annually assessed VMS frequency and annual NTX measurements. Our results show that mean adjusted NTX was 1.94 nM of bone collagen equivalents (BCE)/mM of creatinine higher among early perimenopausal women with any VMS than among early perimenopausal women with no VMS (p<.0001). Mean adjusted NTX was 2.44 nM BCE/mM of creatinine higher among late perimenopausal women with any VMS than among late perimenopausal women with no VMS (p=.03). Among premenopausal women, VMS frequency was not significantly associated with NTX level. When NTX values among women with frequent VMS (≥6 days in past 2 weeks) were expressed as percentages of NTX values among women without frequent VMS, the differences were 3% for premenopausal women, 9% for early perimenopausal women, 7% for late perimenopausal women, and 4% for postmenopausal women. Adjustment for serum follicle-stimulating hormone (FSH) level greatly reduced the magnitudes of associations between VMS and NTX level. We conclude that among early perimenopausal and late perimenopausal women, those with VMS had higher bone turnover than those without VMS. Prior to the final menstrual period, VMS may be a marker for risk of adverse bone health.

KW - bone turnover

KW - Hot flashes

KW - NTX

KW - urinary N-telopeptide

KW - vasomotor symptoms

UR - http://www.scopus.com/inward/record.url?scp=79953046538&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953046538&partnerID=8YFLogxK

U2 - 10.1002/jbmr.259

DO - 10.1002/jbmr.259

M3 - Article

C2 - 20878774

AN - SCOPUS:79953046538

VL - 26

SP - 840

EP - 849

JO - Journal of Bone and Mineral Research

JF - Journal of Bone and Mineral Research

SN - 0884-0431

IS - 4

ER -